

## Press release

### **IBA extends its Positron Emission Tomography (PET) network in the US and reinforces its global coverage**

Embargo until 5:40 pm (Belgian time) – August 31, 2005

**Louvain-la-Neuve, Belgium, August 31, 2005** – IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) today announced that it has acquired four new PET tracers production and distribution centers from Pharmalogic, LLC, a US-based company. The facilities, including cyclotrons, are located in Albany and Long Island (New York State), Boston (Massachusetts) and Totowa (New Jersey).

With this acquisition, IBA reinforces its leadership position in the most densely populated area in the US and extends its coverage. The number of high capacity PET cyclotrons of the IBA worldwide network reaches 20 units, of which 17 in the USA where IBA's PET tracers business operates under the name of Eastern Isotopes. Additional units are under construction worldwide.

Terms of the acquisition were not disclosed. The transaction is not expected to have a significant impact on IBA's earnings in 2005.

In addition to last year's opening of the Gilroy center in California and the acquisition of New Mexico Positron and Lubbock West Texas Positron earlier this year, this new investment supports IBA's global strategy to expand its network worldwide and reinforces its leadership in FDG production and distribution throughout the USA.

“FDG has emerged as a key pharmaceutical for the diagnosis of cancer and several other critical diseases. As an industry leader, we plan to further increase our presence nationwide in the US and elsewhere. This is a very important business segment for IBA and we are actively looking at opportunities as they arise” said Pierre Mottet, Chief Executive Officer.

In addition to the US, IBA is actively working to develop its PET network, notably in Europe and Asia.

#### **About IBA**

IBA delivers efficient, dependable solutions of a unique precision in the fields of cancer diagnosis and therapy. Through its American subsidiary Eastern Isotopes Inc., IBA provides radiopharmaceuticals, notably in the field of Positron Emission Tomography. The company also offers innovative responses to improve the efficacy, hygiene and safety of everyday life through sterilization and ionization solutions. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to BelSmall index.

Website: <http://www.iba-worldwide.com>

#### **Contact**

Paul-Emmanuel Goethals

Director, Corporate Business Development  
& Investor Relations

Tel.: +32 10 47 58 16

[goethals@iba.be](mailto:goethals@iba.be)